Approval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change from baseline in Forced Vital Capacity at 52 weeks with ...

Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month.

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...

Approval is based on results from Phase III FIBRONEERTM-IPF trial, which showed statistically significant improvements in the absolute change from baseline in Forced Vital Capacity at 52 weeks with ...

If you're in the market for a new credit card and struggling to get approved, you've come to the right place. Below, CNBC Select rounded up the easiest credit cards to get — whether you want no annual ...

Actinomyces and CCL11 are identified as significant contributors to idiopathic pulmonary fibrosis through the gut-lung axis. Mendelian randomization implicated 12 gut microbiota taxa and 8 ...

Investing.com -- Tvardi Therapeutics (NASDAQ:TVRD) stock plunged 30% after the company reported disappointing preliminary data from its Phase 2 REVERT trial evaluating TTI-101 in idiopathic pulmonary ...

One item to point out is that Tvardi Therapeutics (NASDAQ:TVRD) brought its pipeline forth to public trading because of a merger it enacted with Cara Therapeutics and thus was able to list on the ...

Stablecoin payment volumes have grown to $19.4B year-to-date in 2025. OwlTing aims to capture this market by developing payment infrastructure that processes transactions in seconds for fractions of a ...